Sponsor study identifier
observational
162
1 country
2
Study Start
May 17, 2021
Actual (reported)Primary Completion
February 21, 2022
Actual (reported)Study Completion
March 10, 2022
Actual (reported)Depression and anxiety in patients with breast cancer is serious comorbidity that affects the quality of life for patients, and their survival rates as they have poorer health outcomes. Furthermore, patients' high psychological burden is linked to higher healthcare costs. The investigation of the depression and anxiety symptoms prevalence among newly diagnosed breast cancer patients will help to navigate the health policy adjustment and psycho-social support system requirements. This study aims to investigate the prevalence of depression and anxiety symptoms among newly diagnosed breast cancer patients in Almaty, Kazakhstan, and associated risk factors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 10, 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 17, 2021
Actual (reported)May 19, 2021
Actual (reported)August 18, 2021
Actual (reported)February 21, 2022
Actual (reported)March 10, 2022
Actual (reported)Prevalence of Depression Symptoms
Prevalence of depression symptoms among newly diagnosed breast cancer patients according to the Beck Depression Inventory-II (BDI-II). The 21-item self-administered survey is scored on a scale of 0-3 in a list of four statements arranged in increasing severity about a particular symptom of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the Beck Depression Inventory-II (BDI-II). There is a four-point scale for each item ranging from 0 to 3. p. On two items (16 and 18) there are seven options to indicate either an increase or decrease of appetite and sleep. Cut-off score guidelines for the BDI-II are given with the recommendation that thresholds be adjusted based on the characteristics of the sample, and the purpose for use of the BDI-II. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.
within 6 months of diagnosis
Prevalence of Anxiety Symptoms
Prevalence of anxiety symptoms among newly diagnosed breast cancer patients according to the Beck Anxiety Inventory. The Beck Anxiety Inventory (BAI) consists of 21 self-reported items (four-point scale ranging from 0 to 3. p.) used to assess the intensity of physical and cognitive anxiety symptoms during the past week. Scores may range from 0 to 63: minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63).
Newly diagnosed breast cancer patients referred to Kazakh Institute of Oncology and Radiology or Almaty Oncology Center will be assessed on the prevalence of depression and anxiety symptoms.
Study population will include breast cancer patients with confirmed diagnosis referred to the treatment to the Kazakh Institute of Oncology and Radiology and the Almaty Oncology Center
Almaty Oncology Center
Almaty, 050000, Kazakhstan
Kazakh Institute of Oncology and Radiology
Almaty, 050000, Kazakhstan
Indira A Karibayeva, MPH
Kazakh Medical University of Continuing Education
162 participants (actual enrollment reported by the registry).
First Submitted
May 19, 2021
First Posted
August 18, 2021
Study Start
May 17, 2021
Actual (reported)Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory
within 6 months of diagnosis
Contact the study team to confirm eligibility.
Primary Completion
February 21, 2022
Actual (reported)Study Completion
March 10, 2022
Actual (reported)Last Updated
March 25, 2022
Record last verified: 2022-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: